Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Cash from Financing Activities (2012 - 2026)

Kamada's (KMDA) quarterly Cash from Financing Activities came in at -$19.0 million in Q2 2026, down 17.85% on a YoY basis from -$23.1 million in Q2 2025, and down 2119.16% quarter-over-quarter from -$856000.0 in Q1 2026.

Analysis

Kamada (KMDA) Cash from Financing Activities (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Cash from Financing Activities for 15 consecutive years, with -$19.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash from Financing Activities fell 17.85% year-over-year to -$19.0 million; the trailing twelve-month figure through Jun 2026 stood at -$21.8 million (up 0.55% YoY), and the FY2025 full-year result was -$18.3 million, down 31.87% from the prior year.
  • Cash from Financing Activities eased to -$19.0 million in Q2 2026 per KMDA's latest filing, from -$856000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $31.3 million in Q3 2023 and bottomed at -$19.0 million in Q2 2026.
  • Historically, Cash from Financing Activities has averaged -$2.2 million across 5 years, with a median of -$2.3 million in 2022.
  • The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 608.78% in 2022, then surged 1484.12% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$2.9 million in 2022, then jumped by 44.93% to -$1.6 million in 2023, then jumped by 55.22% to -$708000.0 in 2024, then tumbled by 66.53% to -$1.2 million in 2025, then plunged by 1511.2% to -$19.0 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$19.0 million, -$856000.0, and -$1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -1.48 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 2.34 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -426.70 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn -1.22 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 14.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 36.24 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 1.30 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -181.51 Mn
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn -19.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -19.00 Mn
Mar 31, 2026 -856,000.00
Dec 31, 2025 -1.18 Mn
Sep 30, 2025 -754,000.00
Jun 30, 2025 -16.12 Mn
Mar 31, 2025 -293,000.00
Dec 31, 2024 -708,000.00
Sep 30, 2024 -4.79 Mn
Jun 30, 2024 -2.68 Mn
Mar 31, 2024 -5.74 Mn
Dec 31, 2023 -1.58 Mn
Sep 30, 2023 31.30 Mn
Jun 30, 2023 -5.86 Mn
Mar 31, 2023 -2.88 Mn
Dec 31, 2022 -2.87 Mn
Sep 30, 2022 -2.26 Mn
Jun 30, 2022 -2.40 Mn
Mar 31, 2022 -1.81 Mn
Dec 31, 2021 19.70 Mn
Sep 30, 2021 -319,000.00